

Supplementary Table 5. Risk prediction models for incident vascular dementia in post-kidney transplantation recipients

Variable	Modela		Modelb	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age grading (yr)				
40–44	0 (0)	>0.99	0 (0)	>0.99
45–49	0.45 (0.09–2.30)	0.33	0.46 (0.09–2.39)	0.36
50–54	1 (Reference)		1 (Reference)	
55–59	1.19 (0.32–4.43)	0.80	1.14 (0.30–4.28)	0.85
60–64	1.95 (0.52–7.27)	0.32	1.94 (0.51–7.35)	0.33
65–69	5.33 (1.43–19.91)	0.01	5.48 (1.40–21.39)	0.01
≥70	0 (0)	>0.99	0 (0)	0.001
Sex				
Female vs. male	0.67 (0.26–1.77)	0.42	0.82 (0.30–2.24)	0.70
Income				
Medical aid	1 (Reference)		1 (Reference)	
Q1	0 (0)	>0.99	0 (0)	>0.99
Q2	1.44 (0.32–6.42)	0.64	0.70 (0.15–3.28)	0.65
Q3	0.76 (0.15–3.79)	0.74	0.34 (0.07–1.78)	0.20
Q4	1.25 (0.34–4.60)	0.74	0.55 (0.14–2.19)	0.40
Diabetes mellitus	4.19 (1.51–11.64)	0.006	3.02 (1.04–8.73)	0.04
Hypertension	27501912 (0)	>0.99	71940 (0)	>0.99
Dyslipidemia	1.60 (0.13–4.07)	0.33	1.09 (0.41–2.90)	0.86
Cardiovascular disease	1.22 (0.44–3.38)	0.71	0.72 (0.25–2.07)	0.54
Dialysis vintage period	0.95 (0.81–1.12)	0.57	0.97 (0.82–1.15)	0.71
Immunosuppressants				
Desensitization	1.19 (0.35–4.12)	0.78	1.10 (0.31–3.92)	0.89
Induction				
ATG	1 (Reference)		1 (Reference)	
Basiliximab	1.33 (0.18–9.97)	0.78	1.31 (0.12–10.07)	0.80
Maintenance CNI				
Tacrolimus	1 (Reference)		1 (Reference)	
Cyclosporine	0.77 (0.22–2.65)	0.68	0.85 (0.25–2.98)	0.80

ATG, antithymocyte globulin; CI, confidence interval; CNI, calcineurin inhibitor; HR, hazard ratio.

^aUnadjusted. ^bAdjusted for age, sex, diabetes mellitus, hypertension, dyslipidemia, income, cardiovascular disease, dialysis vintage period, and immunosuppressants.